Status:
COMPLETED
Personalizing Docetaxel Dosing in Advanced Prostate Cancer
Lead Sponsor:
Physiomics
Collaborating Sponsors:
Portsmouth Hospitals NHS Trust
National Institute for Health Research, United Kingdom
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Patients with advanced prostate cancer are often treated with the chemotherapy drug docetaxel. The manufacturers of this drug suggest using the same dose of drug per m² body surface area for all patie...
Eligibility Criteria
Inclusion
- Diagnosed with metastatic prostate cancer (hormone sensitive or castrate resistant) and histologically confirmed
- Metastatic at disease onset or relapsed disease
- A treatment decision has been made to start a course of docetaxel as part of their standard of care treatment in accordance with the drug's label and the treating clinician's judgement
- Patient has not received a previous cycle of docetaxel within 8 weeks of the date of enrolment
- Life expectancy \> 12 weeks
- Participant is willing and able to give informed consent for participation in the study
Exclusion
- \- Patients with autoimmune disease receiving active treatments Participant is unable to give informed consent
Key Trial Info
Start Date :
July 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04823910
Start Date
July 6 2021
End Date
December 31 2022
Last Update
March 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Portsmouth Hospitals University NHS Trust
Portsmouth, United Kingdom, PO6 3LY